Expert Interviews

Dr Alex Tessnow discusses the key prevalence data stratified by gender and age within a longitudinal, retrospective, database study examining the prevalence of hypothyroidism in a commercially insured US population.

Alex Tessnow M.D. provides a brief overview of the study rationale and design of the recently presented poster highlighting the prevalence of hypothyroidism in a commercially insured US population.

Endocrinology experts discuss the clinical implications of off-target TSH levels and stress the importance of stabilizing these levels for hypothyroidism management.

Endocrinology experts share their practical approaches for monitoring TSH levels and providing follow-up to hypothyroidism treatment.

Experts in endocrinology share their insights into the clinical practicalities of the different types and formulations of levothyroxine treatment in patients with hypothyroidism.

Drs James Hennessey and Antonio Bianco share their insights into the role that diet and calorie restriction can have on thyroid-stimulating hormone[TSH] levels for patients with hypothyroidism.

Antonio Bianco, MD, PhD, shares considerations for using consistent LT4 formulation and highlights the role of pharmacists in maintaining consistent LT4 prescriptions for patients with hypothyroidism.

Drs James Hennessey and Antonio Bianco talk about the optimization of levothyroxine in elderly patients with hypothyroidism.

James Hennessey, MD, FACP, and Antonio Bianco, MD, PhD, discuss the role of age and concomitant drug interactions in maintaining optimal TSH levels for hypothyroidism management.

Experts in endocrinology review the impact of proper and consistent treatment adherence to maintain TSH levels and the role diet and dosing timing plays in managing hypothyroidism.

James Hennessey, MD, FACP, provides an overview of clinical trial data for patients with hypothyroidism, highlighting the negative effect and poor health-related consequences of off target TSH levels.

Experts in endocrinology comment on the importance of maintaining TSH levels in normal target ranges and highlight the prevalence of patients with hypothyroidism not maintaining these targets.

Drs James Hennessey and Antonio Bianco examine the differences in prevalence between overt and subclinical hypothyroidism.

James Hennessey, MD, FACP, and Antonio Bianco, MD, PhD, discuss the prevalence of hypothyroidism and the role of thyroid hormone replacement therapy in managing the condition.

Charles Montano, MD, and Carmen Kosicek, MSN, PMHNP-BC, provide advice regarding monitoring for adverse events and compliance with different classes of MDD treatment and review suggestions for follow-up and special patient populations.

Experts in psychiatry share their thoughts on the perception of MDD within the healthcare community and the implications of this condition being viewed as chronic vs episodic.

How to keep family planning conversations in primary care? First, you have to have them, says UC San Francisco professor of family community medicine, Christine Dehlendorf, MD, MAS.

Clinician-directed conversations on contraception and family planning remove patients from the center of the visit which is where must be in a shared decision-making model.

Carmen Kosicek, MSN, PMHNP-BC, and Charles Montano, MD, comment on the interplay between depression and other comorbid psychiatric and medical health conditions as well as the economic impact of MDD.

Charles Montano, MD; Carmen Kosicek, MSN, PMHNP-BC; and Gus Alva, MD, DFAPA, review the impact of the duration of MDD episodes and goals of managing episode recurrences.

Ordering an obesity phenotype should be as simple and routine as ordering an HbA1c or a lipid panel, says obesity expert Andres Acosta, MD, PhD.

Obesity physician-scientist Andres Acosta, MD, PhD, reviews findings from recent studies he led that suggest true potential for phenotype-focused weight loss intervention.

Obesity phenotyping uses a battery of validated tests and procedures to determine the root cause of a patient's disease and then match treatment accordingly.

Mayo Clinic's Andres Acosta, MD, PhD, details the 4 biologic obesity phenotypes his team has identified and how their use can change weight loss outcomes.

Acosta, a pioneer in the phenotyping of obesity, says one-third of patients don't respond to treatment and he knows why.

Use of GLP-1 mimetics and SGLT-2 inhibitors for cardiorenal protection in T2D patients is backed by robust clinical trial evidence, says AACE President Sethu Reddy, MD.

AACE president Dr Sethu Reddy highlights evidence-based updates, including selection of diabetes medication based on comorbidities and new agents to treat DKD and elevated lipids.

Reddy talks about the value of A1c vs results of an OGTT for T2D diagnosis, about glycemic targets and patient safety, hyperglycemia during pregnancy, and more in our interview.

A small-town physician offers words of encouragement to his peers.

AAFP Board Chair Ransone points to recent data that show two-thirds of long COVID patients are already treated in primary care settings.